Skip to main content

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis

Active, not recruiting · Phase 3 · NCT06025578

Conditions: Progressive Pulmonary Fibrosis

At a glance

Research payments reported, 2025
$56,540
U.S. investigators named
22
Sites paid
1
Planned or actual enrollment
1,057

About the trial

Sponsor
Bristol-Myers Squibb
Tested
BMS-986278 (drug), BMS-986278 Placebo (drug)
Dates
Started 2023-10-25; completion 2027-12-27
Results posted
Not yet

The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.

From ClinicalTrials.gov, last updated 2026-04-23. Full record, eligibility and contacts (opens in a new tab)

Industry funding

E.r. Squibb & Sons, L.l.c. reported $56,540 in research payments for this study in 2025 (22 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • Advarra $56,540

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.